Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, -Radiation Dosimetry, and Preliminary Anti-Neoplastic Activity of LNTH-2403, a LRRC15-targeted 177Lutetium-labeled Monoclonal Antibody, in Participants With Relapsed / Refractory Osteosarcoma

NCT07357519 is registered in ClinicalTrials.gov with Lantheus Medical Imaging as lead sponsor.

NCT NCT07357519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07357519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, -Radiation Dosimetry, and Preliminary Anti-Neoplastic Activity of LNTH-2403, a LRRC15-targeted 177Lutetium-labeled Monoclonal Antibody, in Participants With Relapsed / Refractory Osteosarcoma
Lead sponsor
Lantheus Medical Imaging
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 3, 2026
Completion date
May 31, 2032
Enrollment
55 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed / refractory osteosarcoma